- ICH GCP
- US Clinical Trials Registry
- Klinisk utprøving NCT01036490
Exercise in Obese Diabetic Patients With Chronic Kidney Disease (EX-ODCKD)
Structured Exercise in Obese Diabetic Patients With Chronic Kidney Disease
Studieoversikt
Detaljert beskrivelse
Patients with type 2 diabetes, obesity, and chronic kidney disease (CKD) are generally physically inactive, have a high mortality rate, and may benefit from an exercise program. However, there have been no randomized controlled trials to determine the benefits of exercise training in this population. This study seeks to substantiate the hypothesis that increasing energy expenditure by exercise training in the obese diabetic patient with CKD will result in the following benefits:
- Renal benefits, including reduction in proteinuria and stabilization of glomerular filtration rate (GFR)
- Cardiovascular benefits, including decreased blood pressure, decreased heart rate, and increased exercise tolerance.
- Improved glucose control (lower glycated hemoglobin), lipid control (decreased cholesterol with improved atherogenic profile)
- Improved body composition (weight loss, increased lean body mass and decreased fat mass).
- Decreased inflammation (assessed by high-sensitivity C-reactive protein), endothelial dysfunction (assessed by flow-mediated dilatation), and oxidative stress (assessed by reduced glutathione).
- Increased health-related quality of life.
In preparation for this proposal, the investigators performed a 24-week randomized controlled feasibility study comparing aerobic exercise plus optimal medical management to medical management alone in patients with type 2 diabetes, obesity (BMI > 30 kg/m2), and stage 2-4 CKD (eGFR 15-90 mL/min/1.73m2) with persistent proteinuria of > 200 mg/g. Subjects randomized to exercise underwent thrice weekly aerobic training for 6 followed by 18 weeks of supervised home exercise. The primary outcome variable was change in proteinuria. Exercise training resulted in a significant improvement in exercise duration during stress testing which persisted until 24 weeks. This was accompanied by significant decreases in resting systolic blood pressure and 24-hour proteinuria at 24 weeks. No changes were seen in the control group. The investigators concluded that exercise training in obese diabetic patients with CKD is feasible and results in a demonstrable training effect (increased exercise duration and decreased resting blood pressure). Moreover, it may decrease proteinuria and thus have a renoprotective effect.
The investigators now propose a larger-scale randomized controlled trial to determine the effects of exercise on renal functions, cardiovascular fitness, inflammation, and oxidative stress in diabetic patients with CKD. This will be a 52-week randomized study based on the investigators' pilot study design with some modifications. As opposed to the 6-week training period and 18-week home exercise period utilized in the pilot study, subjects randomized to exercise will undergo 12 weeks of intensive exercise training in the exercise laboratory followed by 40 weeks of supervised home exercise training (total duration of study 1 year). Moreover, due to recent recommendations that resistance training be incorporated into exercise training regimens in type 2 diabetic patients, the investigators will incorporate resistance (strength) training in this proposal. The primary outcome variable will be change in proteinuria at 12 and 52 weeks. Secondary outcome variables will be change in albuminuria and estimated glomerular filtration rate (eGFR) at 12 and 52 weeks. In addition, the investigators will measure blood pressure (BP), glycated hemoglobin, lipid profile, C-reactive protein (CRP) levels, body weight and composition, endothelial dysfunction (by flow-mediated dilatation), and Quality of Life (QoL) evaluations. The Index of Coexistent Diseases (ICED) to measure comorbidities to determine if comorbid conditions had any influence on the outcomes of the study. The Center for Epidemiologic Studies Depression Scale (CES-D) will also be used to determine the influence of depression (covariate) on study outcomes and adherence with the study objectives.
This study will directly address the effects of a structured exercise program in a patient population at high risk for cardiovascular complications. The investigators will specifically address the novel idea that exercise will not only improve cardiovascular fitness but will also ameliorate the renal complications resulting from diabetes.
Studietype
Registrering (Faktiske)
Fase
- Ikke aktuelt
Kontakter og plasseringer
Studiesteder
-
-
Illinois
-
Hines, Illinois, Forente stater, 60141-5000
- Edward Hines Jr. VA Hospital, Hines, IL
-
-
Deltakelseskriterier
Kvalifikasjonskriterier
Alder som er kvalifisert for studier
Tar imot friske frivillige
Kjønn som er kvalifisert for studier
Beskrivelse
Inclusion Criteria:
- Diabetes mellitus
- CKD Stages 2-4
- BMI > 30
- Persistent proteinuria (urine protein/creatinine > 200 mg/g for > 3 mo)
- On treatment with ACE inhibitor or ARB
- On treatment with aspirin
- On treatment with statin (if LDL > 100)
Exclusion Criteria:
- Symptomatic neuropathy/retinopathy
- Positive stress test due to coronary arterial disease
- Symptomatic cardiovascular disease
- Congestive heart failure (New York Heart Association Class III or IV)
- Chronic obstructive pulmonary disease (FEV1 < 50% predicted and/or requires supplemental oxygen support during exercise)
- Complaints of angina during the stress test
- Cerebrovascular disease/cognitive impairment
- Renal transplant
- Inability to walk on the treadmill
- Any unforeseen illness or disability that would preclude exercise testing or training
- Participation in a formal exercise program within the previous 12 weeks
Studieplan
Hvordan er studiet utformet?
Designdetaljer
- Primært formål: Behandling
- Tildeling: Randomisert
- Intervensjonsmodell: Parallell tildeling
- Masking: Ingen (Open Label)
Våpen og intervensjoner
Deltakergruppe / Arm |
Intervensjon / Behandling |
---|---|
Ingen inngripen: Styre
Kontrollgruppe
|
|
Eksperimentell: Exercise
Exercise Group
|
Exercise training for 12 weeks followed by home exercise for 40 weeks
|
Hva måler studien?
Primære resultatmål
Resultatmål |
Tidsramme |
---|---|
Change in Proteinuria
Tidsramme: 12 weeks minus baseline
|
12 weeks minus baseline
|
Change in Proteinuria
Tidsramme: 52 weeks minus baseline
|
52 weeks minus baseline
|
Sekundære resultatmål
Resultatmål |
Tidsramme |
---|---|
Change in Albuminuria
Tidsramme: 12 weeks minus baseline
|
12 weeks minus baseline
|
Change in Albuminuria
Tidsramme: 52 weeks minus baseline
|
52 weeks minus baseline
|
Change in Estimated Glomerular Filtration Rate (eGFR)
Tidsramme: 12 weeks minus baseline
|
12 weeks minus baseline
|
Change in Estimated Glomerular Filtration Rate (eGFR)
Tidsramme: 52 weeks minus baseline
|
52 weeks minus baseline
|
Samarbeidspartnere og etterforskere
Etterforskere
- Hovedetterforsker: Eileen G. Collins, PhD RN, Edward Hines Jr. VA Hospital, Hines, IL
- Hovedetterforsker: David J Leehey, Edward Hines Jr. VA Hospital, Hines, IL
Publikasjoner og nyttige lenker
Studierekorddatoer
Studer hoveddatoer
Studiestart (Faktiske)
Primær fullføring (Faktiske)
Studiet fullført (Faktiske)
Datoer for studieregistrering
Først innsendt
Først innsendt som oppfylte QC-kriteriene
Først lagt ut (Anslag)
Oppdateringer av studieposter
Sist oppdatering lagt ut (Faktiske)
Siste oppdatering sendt inn som oppfylte QC-kriteriene
Sist bekreftet
Mer informasjon
Begreper knyttet til denne studien
Ytterligere relevante MeSH-vilkår
Andre studie-ID-numre
- F7264-R
Plan for individuelle deltakerdata (IPD)
Planlegger du å dele individuelle deltakerdata (IPD)?
Legemiddel- og utstyrsinformasjon, studiedokumenter
Studerer et amerikansk FDA-regulert medikamentprodukt
Studerer et amerikansk FDA-regulert enhetsprodukt
produkt produsert i og eksportert fra USA
Denne informasjonen ble hentet direkte fra nettstedet clinicaltrials.gov uten noen endringer. Hvis du har noen forespørsler om å endre, fjerne eller oppdatere studiedetaljene dine, vennligst kontakt register@clinicaltrials.gov. Så snart en endring er implementert på clinicaltrials.gov, vil denne også bli oppdatert automatisk på nettstedet vårt. .
Kliniske studier på Kronisk nyre sykdom
-
Clínica de Oftalmología de Cali S.AFullførtMeibomian kjerteldysfunksjon | Eyes Dry ChronicColombia
-
Medical University of ViennaFullførtSekundær hyperparathyroidisme | CKD-MBD - Chronic Kidney Disease Mineral and Bone Disorder | NyreerstatningØsterrike
-
Alcon ResearchFullført
-
Jules Bordet InstituteMacopharma; Belgian Hematological SocietyRekrutteringRefractory Chronic Graft Versus Host Disease (cGVHD)Belgia
-
Occyo GmbHUniversity Clinic for Ophthalmology and Optometry- SalzburgFullførtLimbal stamcelle mangel | Hornhinnesykdom | Eyes Dry Chronic | Kronisk konjunktivitt i begge øyne | Øyelesjon | Øyesykdom; Grå stær | Øyne Tørr følelse av | Hornhinne betent | Hornhinne; Skade, slitasje | HornhinneinfeksjonØsterrike
-
Novartis PharmaceuticalsTilgjengeligPrimær myelofibrose (PMF) | Polycytemi Vera (PV) | Post polycytemi myelofibrose (PPV MF) | Trombocytemi myelofibrose (PET-MF) | Alvorlig/svært alvorlig COVID-19-sykdom | Steroid Refractory Acute Graft Versus Host Disease (SR aGVHD) | Steroid Refractory Chronic Graft Versus Host Disease (SR cGVHD)